Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 20/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 18/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 15/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2245724 | 1.00 | OPRL1 (0.52) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL7883594 | 1.00 | OPRL1 (0.52) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL7889646 | 0.88 | CHRNA7 (0.45) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL3595175 | 0.79 | OPRL1 (0.42) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL3595173 | 0.79 | OPRL1 (0.42) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL13177689 | 0.78 | OPRL1 (0.54) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL12022257 | 0.77 | OPRL1 (0.54) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL11574522 | 0.76 | OPRL1 (0.44) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL14981248 | 0.76 | OPRL1 (0.51) | OPRL1OPRM1OPRK1OPRD1 | |
| Hydrochloric Acid SCHEMBL9983931 | 0.76 | OPRL1 (0.53) | OPRL1OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877779-B2 | Benzimidazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-11-04 | — | — | US | disclosed |
| EP-2397477-B1 | Heterocyclic-substituted piperidine compounds and the uses thereof | PURDUE PHARMA LP (US) | 2014-03-05 | — | — | EP | disclosed |
| EP-2397477-B1 | Heterocyclic-substituted piperidine compounds and the uses thereof | PURDUE PHARMA LP (US) | 2014-03-05 | — | — | EP | disclosed |
| US-8637502-B2 | 2,3,4,5-tetrahydro-benzo{B}{1,4}diazepine-comprising compounds of formula(III) for treating pain | Purde Pharma L.P. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637502-B2 | 2,3,4,5-tetrahydro-benzo{B}{1,4}diazepine-comprising compounds of formula(III) for treating pain | Purde Pharma L.P. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637502-B2 | 2,3,4,5-tetrahydro-benzo{B}{1,4}diazepine-comprising compounds of formula(III) for treating pain | Purde Pharma L.P. (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2280008-B1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINES AS ORL-1 LIGANDS | PURDUE PHARMA LP (US) | 2013-05-29 | — | — | EP | disclosed |
| EP-2280008-B1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINES AS ORL-1 LIGANDS | PURDUE PHARMA LP (US) | 2013-05-29 | — | — | EP | disclosed |
| EP-1491212-B1 | REMEDY FOR SLEEP DISTURBANCE | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-08-08 | — | — | EP | disclosed |
| EP-1491212-B1 | REMEDY FOR SLEEP DISTURBANCE | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-08-08 | — | — | EP | disclosed |
| EP-2076506-A2 | HETEROCYCLIC-SUBSTITUTED PIPERIDINES AS ORL-1 LIGANDS | Purdue Pharma L.P. (US) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008089201-A2 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE AS ORL-1 LIGANDS | PURDUE PHARMA L.P. (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008089201-A2 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE AS ORL-1 LIGANDS | PURDUE PHARMA L.P. (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20050119308-A1 | Remedy for sleep disturbance | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-06-02 | — | — | US | disclosed |
| EP-0963987-B1 | Spiro(piperidine-4,1'-pyrrolo(3,4-c)pyrrole) | HOFFMANN LA ROCHE (CH) | 2002-08-28 | — | — | EP | disclosed |
| EP-0856514-B1 | 8-substituted-1,3,8-triazaspiro[4.5]decan-4-on derivatives | HOFFMANN LA ROCHE (CH) | 2001-06-13 | — | — | EP | disclosed |
| US-6075034-A | Spiro[piperidine-4,1'-pyrrolo [3,4-C] pyrrole]derivatives | HOFFMANN-LA ROCHE INC. (US) | 2000-06-13 | — | — | US | disclosed |
| US-6071925-A | ANTIDEPRESSANTS, ANTICONVULSANTS OR ANTIANXIETY AGENTS, ALSO FOR TREATMENT OF MEMORY LOSS IN ALZHEIMER'S DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2000-06-06 | — | — | US | disclosed |
| EP-0963987-A2 | Spiro(piperidine-4,1'-pyrrolo(3,4-c)pyrrole) | F. HOFFMANN-LA ROCHE AG (CH) | 1999-12-15 | — | — | EP | disclosed |
| EP-0856514-A1 | 8-substituted-1,3,8-triazaspiro[4.5]decan-4-on derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1998-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119308-A1 | Remedy for sleep disturbance | PER2, HCRTR1, HCRTR2 | OPRL1 10/4885OPRM1 115/4885OPRK1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.